J. Michael Dixon, MBChB, MD, Professor of Surgery, Consultant Surgeon, University of Edinburgh, Clinical Director of the Edinburgh Breast Unit, Western General Hospital, Edinburgh, Scotland, discusses the need to develop a better way of informing women with breast cancer of the potential risks entailed by a mastectomy, including mastectomy with breast reconstruction.
Dixon explains, in the UK approximately 10% of women receiving breast reconstruction following mastectomy experienced a complication that resulted in the loss of their implant. Readmission following mastectomy reaches 10-20%, he notes, this number is exceptionally high when you consider the procedure has not been associated with a reduced rate of local recurrence.
The need for education is an ongoing item, as is the need to increase awareness in the US. Dixon notes, there is currently a large disparity between the UK and the US. He adds that more women in the US are needlessly receiving mastectomy causing additional risks when breast-conserving surgery is the better option.
Although the potential for next-generation sequencing of breast cancer tumors to improve treatment strategies is widely recognized, questions swirl about the optimal use of such increasingly available technologies in clinical practice for today’s patients.
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression